An overview of treatment outcomes for patients with Crohn’s disease showed no discernable patterns in clinical remission and response has emerged in recent years.1
A team, led by Fernando Magro, Department of Gastroenterology, São João University Hospital Center, identified time trends in clinical response and clinical remission rates for patients with Crohn’s disease treated with biologics.
Biologics
In recent years there has been a flux of biologics to garner approval from the US Food and Drug Administration (FDA), for either Crohn’s disease or ulcerative colitis.
“Over the last decade, the number of biological agents with alternative mechanisms of action has gradually increased, resulting in considerable number of therapeutic options for patients with IBD,” the authors wrote.